Evaluation of biomarker for advanced age-related macular degeneration using Nanotrap® particles

POSTER Evaluation of a plasma biomarker for advanced age-related macular degeneration using Nanotrap® particle–enabled proteomics


Thirty plasma samples were used from the AMD Registry that had previously been analyzed for 4001 proteins using the SOMAscan® platform. Samples included 10 age-matched patients with bilateral geographic atrophy AMD (GA), 10 neovascular AMD (NV), and 10 healthy controls (HC) without retinal disease. Ceres Nanosciences’ Nanotrap® particles were used to enrich proteins from 50 microliters of plasma from the same samples prior to LC/MS analysis. Statistical approaches were used for validation of vinculin, data mining, and identification of improved candidate markers of disease.


Using an independent analytic technique enabled by Nanotrap® particle enrichment to drastically improve plasma proteome coverage, we have confirmed that plasma vinculin is elevated in advanced AMD compared with controls. These results confirm a previous report in NV patients by Kim, et al in 2014, and our previous work using the SOMAscan® platform.


The Nanotrap® particle-LC/MS approach identified more than 100 novel proteins that exhibited more significant changes between disease state and controls than vinculin.


See full poster here

  • LinkedIn Classic
  • Twitter App Icon
  • Facebook Social Icon

9460 Innovation Drive, Manassas, VA, 20110, United States

800-615-0418 / info@ceresnano.com

© 2020 Ceres Nanosciences, Inc. All Rights Reserved